- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.03. | Seer, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| 04.03. | Seer, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 02.03. | Seer, Inc. (SEER) Q4 2023 Earnings Call Transcript | 1 | Insider Monkey | ||
| 01.03. | Earnings call: Seer reports growth and outlines future proteomics strategy | 2 | Investing.com | ||
| 01.03. | Seer Inc reports results for the quarter ended in December - Earnings Summary | 2 | Reuters | ||
| 29.02. | Seer GAAP EPS of -$0.28 beats by $0.10, revenue of $4.4M beats by $0.35M | 1 | Seeking Alpha | ||
| 29.02. | Seer, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.02. | Seer, Inc.: Seer Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Outlook | 234 | GlobeNewswire (Europe) | REDWOOD CITY, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial... ► Artikel lesen | |
| 21.02. | Seer, Inc.: Seer to Participate in the TD Cowen 44th Annual Health Care Conference | 1 | GlobeNewswire (USA) | ||
| 01.02. | Seer, Inc.: Seer to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024 | 3 | GlobeNewswire (USA) | ||
| 22.12.23 | Seer, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.12.23 | Seer, Inc.: Seer to Present at the J.P. Morgan 42nd Annual Health Care Conference | 1 | GlobeNewswire (USA) | ||
| 17.11.23 | Seer, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 10.11.23 | Seer, Inc.: Seer to Present at the Canaccord MedTech, Diagnostics and Digital Health & Services Forum | 2 | GlobeNewswire (USA) | ||
| 08.11.23 | Seer Inc reports results for the quarter ended in September - Earnings Summary | 2 | Reuters | ||
| 08.11.23 | Seer, Inc.: Seer Wins Proteomics Solution of the Year by BioTech Breakthrough and Named #5 on Deloitte Technology Fast 500 | 2 | GlobeNewswire (USA) | ||
| 08.11.23 | Earnings call: Seer projects lower revenue amid macroeconomic challenges, continues market expansion | 2 | Investing.com | ||
| 07.11.23 | Seer, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 07.11.23 | Seer, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 07.11.23 | Seer, Inc.: Seer Reports Third Quarter 2023 Financial Results | 151 | GlobeNewswire (Europe) | REDWOOD CITY, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today reported financial results... ► Artikel lesen |
Seite:
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 81,25 | +0,68 % | Besser als BioNTech oder Moderna? Diese Aktie schlägt den Markt seit Jahren - kann sie das wieder? | Sie ist etabliert, zahlt eine Dividende und liefert schon lange eine überdurchschnittliche Performance ab. Diese Biotech-Aktie sollten Anleger auf dem Schirm haben. Das US-Biotech-Unternehmen Amgen... ► Artikel lesen | |
| CUREVAC | 2,200 | +2,80 % | CureVac Aktie: Tiefpunkt trotz nahender Quartalszahlen? | Die CureVac-Aktie durchlebte eine turbulente Woche und notiert aktuell bei 2,3 €, was einem Rückgang von 0,09% im Vergleich zur Vorwoche entspricht. Nach einem Sturz unter die bisherigen Tiefststände... ► Artikel lesen | |
| EPIGENOMICS | 1,580 | -3,07 % | EQS-NVR: Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Epigenomics AG
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,854 | +1,67 % | Aufholjagd BioTech 2024 - jetzt positionieren! Bayer, BioNTech, Defence Therapeutics, Evotec, BioNxt und Vidac Pharma im Fokus | BioTech-Investoren haben im Jahr 2024 bislang noch keine große Party feiern können. Das blieb eher den Spekulanten in den Sektoren Künstliche Intelligenz und Rüstung vorbehalten. Doch nun neigen sich... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,780 | 0,00 % | Il Granaio delle Idee and Ginkgo Bioworks Announce Strategic Collaboration to Optimize Sourdough Strains for Bakery Products | IGDI will leverage Ginkgo's Adaptive Laboratory Evolution technology to improve its sourdough starter culture product PADUA, Italy and BOSTON, April 16, 2024 /PRNewswire/ -- Il Granaio delle Idee... ► Artikel lesen | |
| HALOZYME THERAPEUTICS | 37,060 | +3,32 % | Halozyme Therapeutics, Inc.: Halozyme Reports Fourth Quarter And Full Year 2023 Financial And Operating Results | Reiterating 2024 Financial Guidance: Total Revenue of $915 -985 Million, Representing YOY Growth of 10-19%, Adjusted EBITDA of $535 -585 Million, Representing YOY Growth of 26- 37% and Non-GAAP Diluted... ► Artikel lesen | |
| IMMUNITYBIO | 4,820 | +1,28 % | Pre-market Movers: Abeona Therapeutics, HWH International, ImmunityBio, Hibbett, AGBA Group | NORWALK (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.55 A.M. ET).In the Green HWH International Inc. (HWH) is up over 42% at $1.83.
ImmunityBio... ► Artikel lesen | |
| BEAM THERAPEUTICS | 21,600 | 0,00 % | Expert Ratings For Beam Therapeutics | ||
| ONCOLYTICS BIOTECH | 1,010 | -1,94 % | Oncolytics Biotech® Inc.: Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting | SAN DIEGO and CALGARY, AB, April 25, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology,... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,840 | 0,00 % | Best biotech stocks to buy and hold in 2024: VKTX, SANA, RXRX | ||
| ARCTURUS THERAPEUTICS | 26,170 | 0,00 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| ASSERTIO | 0,785 | 0,00 % | Assertio Holdings, Inc. to Report First Quarter 2024 Financial Results on May 6, 2024 | ||
| SIGA TECHNOLOGIES | 8,640 | 0,00 % | SIGA Technologies - Positive signals abound | SIGA Technologies announced a strategic step in fortifying its distribution partner, Meridian, allowing greater control over planning and executing its international development efforts, a key growth... ► Artikel lesen | |
| MERRIMACK PHARMACEUTICALS | 14,730 | 0,00 % | Merrimack Pharmaceuticals, Inc. Reports Full Year 2023 Financial Results | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") today announced its full year 2023 financial results for the period ended December... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 7,630 | 0,00 % | How Vir found the one: CEO Marianne De Backer |
SEER INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,750 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
